Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback